Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
äŒæ¥ã³ãŒãEOLS
äŒç€ŸåEvolus Inc
äžå Žæ¥Feb 08, 2018
æé«çµå¶è²¬ä»»è
ãCEOãMoatazedi (David)
åŸæ¥å¡æ°332
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 08
æ¬ç€Ÿæåšå°520 Newport Center Dr Ste 1200
éœåžNEWPORT BEACH
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·92660-7022
é»è©±çªå·19492844555
ãŠã§ããµã€ãhttps://www.evolus.com/
äŒæ¥ã³ãŒãEOLS
äžå Žæ¥Feb 08, 2018
æé«çµå¶è²¬ä»»è
ãCEOãMoatazedi (David)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã